Literature DB >> 1683108

[Ocular hypotensive effects of topically applied bunazosin, an alpha 1-adrenoceptor blocker, in rabbits and cats].

K Nishimura1, E Shirasawa, M Kinoshita, M Hikida, Y Kuwayama.   

Abstract

Effects of topically applied bunazosin, an alpha 1-adrenoceptor blocker, on intraocular pressure (IOP) and pupillary diameter were investigated in normotensive rabbits and cats, in addition to experimentally hypertensive rabbits. Bunazosin (0.005% to 0.1%) applied to both eyes significantly lowered IOP in a concentration-dependent manner in normotensive rabbits and cats. The unilateral application of 0.1% bunazosin significantly lowered the IOP in the treated eye, whereas it caused no significant change in the contralateral eye, suggesting that the effect of bunazosin is due mainly to a direct and local action and is not systemic. Bunazosin was also effective in experimentally hypertensive models induced both by water-loading and by alpha-chymotrypsin in rabbits. There was a significant correlation between the IOP decrease caused by bunazosin and the IOP value before the application, indicating that the IOP-lowering action of bunazosin is dependent on the height of the original IOP level. Bunazosin had no influence on pupillary diameter even when 0.5% was applied to rabbits. Topically applied bunazosin may be useful as a new antiglaucoma agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683108

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  2 in total

1.  Comparative study on the combined effects of bunazosin and nipradilol or timolol on intraocular pressure in normotensive rabbits.

Authors:  Masahiro Orihashi; Yuichiro Shima; Hiroshi Tsuneki; Ikuko Kimura
Journal:  Jpn J Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 2.447

2.  Ocular pharmacokinetic/ pharmacodynamic modeling for bunazosin after instillation into rabbits.

Authors:  Koji Sakanaka; Kouichi Kawazu; Masahide Tomonari; Takashi Kitahara; Mikiro Nakashima; Shigeru Kawakami; Koyo Nishida; Junzo Nakamura; Hitoshi Sasaki
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.